4D Molecular Therapeutics (FDMT) Accumulated Depreciation & Amortization (2019 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $21.3 million as the latest value for Q4 2025.
- Quarterly Accumulated Depreciation & Amortization rose 28.3% to $21.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.3 million through Dec 2025, up 28.3% year-over-year, with the annual reading at $21.3 million for FY2025, 28.3% up from the prior year.
- Accumulated Depreciation & Amortization for Q4 2025 was $21.3 million at 4D Molecular Therapeutics, up from $20.1 million in the prior quarter.
- The five-year high for Accumulated Depreciation & Amortization was $21.3 million in Q4 2025, with the low at $4.2 million in Q1 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $11.2 million, with a median of $10.3 million recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization surged 61.32% in 2023, then grew 28.3% in 2025.
- Over 5 years, Accumulated Depreciation & Amortization stood at $5.3 million in 2021, then soared by 45.13% to $7.7 million in 2022, then soared by 54.4% to $11.9 million in 2023, then soared by 39.0% to $16.6 million in 2024, then increased by 28.3% to $21.3 million in 2025.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $21.3 million, $20.1 million, and $18.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.